All In Biotech

Drug Trial Radar · NCT04630808

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 696 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

696

Actual

Start

Nov 9, 2020

Primary completion

Apr 11, 2025

Study completion Jun 25, 2025

Sponsor

Lead sponsor
Nicox Ophthalmics, Inc.Industry
Sponsor type
Industry
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

Conditions

  • Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • NCX 470 0.1%Drug

    NCX 470 Ophthalmic Solution, 0.1%

  • Latanoprost 0.005%Drug

    Latanoprost Ophthalmic Solution, 0.005%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline IOPTime frame: Up to 3 months

Locations

88 sites in 2 countries. Site status is shown where the registry gives one.

  • Nicox Clinical Site

    Dothan, Alabama

  • Nicox Clinical Site

    Chandler, Arizona

  • Nicox Clinical Site

    Phoenix, Arizona

  • Nicox Clinical Site

    Burbank, California

  • Nicox Clinical Site

    Garden Grove, California

  • Nicox Clinical Site

    Huntington Beach, California

  • Nicox Clinical Site

    La Jolla, California

  • Nicox Clinical Site

    Murrieta, California

  • Nicox Clinical Site

    Newport Beach, California

  • Nicox Clinical Site

    Pasadena, California

  • Nicox Clinical Site

    Petaluma, California

  • Nicox Clinical Site

    Redlands, California

  • Nicox Clinical Site

    San Francisco, California

  • Nicox Clinical Site

    Danbury, Connecticut

  • Nicox Clinical Site

    Boynton Beach, Florida

  • Nicox Clinical Site

    Delray Beach, Florida

  • Nicox Clinical Site

    Fort Lauderdale, Florida

  • Nicox Clinical Site

    Fort Myers, Florida

  • Nicox Clinical Site

    Jacksonville, Florida

  • Nicox Clinical Site

    Jupiter, Florida

  • Nicox Clinical Site

    Lakeland, Florida

  • Nicox Clinical Site

    Largo, Florida

  • Nicox Clinical Site

    Mt. Dora, Florida

  • Nicox Clinical Site

    Venice, Florida

  • Nicox Clinical Site

    Morrow, Georgia

  • Nicox Clinical Site

    Roswell, Georgia

  • Nicox Clinical Site

    Peoria, Illinois

  • Nicox Clinical Site

    Rock Island, Illinois

  • Nicox Clinical Site

    Indianapolis, Indiana

  • Nicox Clinical Site

    Bangor, Maine

  • Nicox Clinical Site

    Boston, Massachusetts

  • Nicox Clinical Site

    Lancaster, Massachusetts

  • Nicox Clinical Site

    Grand Rapids, Michigan

  • Nicox Clinical Site

    Chaska, Minnesota

  • Nicox Clinical Site

    Kansas City, Missouri

  • Nicox Clinical Site

    St Louis, Missouri

  • Nicox Clinical Site

    Clifton Park, New York

  • Nicox Clinical Site

    The Bronx, New York

  • Nicox Clinical Site

    Troy, New York

  • Nicox Clinical Site

    Asheville, North Carolina

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.